Kevin J. Fitzgerald, Ph.D.

Kevin J. Fitzgerald, Ph.D.

Executive Vice President, Chief Scientific OfficeratAlnylam Pharmaceuticals· In proxies 2022–2024

Pay in FY2024-4% from the year before · Alnylam Pharmaceuticals stock +22.9% the same year

Kevin J. Fitzgerald, Ph.D. was paid $2.7M in FY2024 (Dec), down 4%. Alnylam Pharmaceuticals stock rose 22.9% that year.

Pay$100 in the stock at the end of FY21 → $139
Pay is from the Summary Compensation Table of each Alnylam Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Alnylam PharmaceuticalsPublic company · 4 yr
    • Executive Vice President, Chief Scientific Officer2022 – Present · 4 yrStock in role +44%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?